Sanguine Biosciences Achieves ISO Certifications
Sanguine Biosciences, a leading company in biospecimen procurement, is dedicated to advancing personalized medicine and biomedical research. Recently, it proudly announced the attainment of three important ISO certifications: ISO 9001, ISO 27001, and ISO 27701. These certifications highlight Sanguine's steadfast commitment to maintaining high standards in quality, information security, and privacy management.
Commitment to Quality Management
The ISO 9001 certification is a testament to Sanguine's strong quality management system (QMS). Brian Neman, the CEO of Sanguine Biosciences, expressed pride in this accomplishment, stating that it reflects their ongoing dedication to excellence in every aspect of their business. This certification ensures that Sanguine adheres to the highest quality standards, which is essential for ensuring customer satisfaction.
Focus on Information Security
In today's world, where data breaches and security threats are increasingly common, Sanguine's ISO 27001 certification is a significant milestone. Gerald Lee, the company’s Chief Privacy Officer (CPO), emphasized the critical nature of protecting information assets. He noted that achieving ISO 27001 certification underscores their commitment to safeguarding the data of customers, partners, and donors with the highest level of security.
Prioritizing Privacy Compliance
In addition to its focus on quality and information security, Sanguine places a strong priority on privacy management. AnnMarie Fleshman, the Vice President of Quality and Compliance, articulated that privacy is a fundamental right. The ISO 27701 certification reflects their dedication to responsibly managing personal data, providing customers with the assurance that their information is handled with care.
Significance of Latest ISO Certifications
The acquisition of these three ISO certifications serves as a strong endorsement of Sanguine's rigorous standards. They provide customers and partners with confidence in the company’s reliable processes and practices. With these ISO certifications reinforcing its commitment to excellence, Sanguine is well-positioned to introduce Good Manufacturing Practices (GMP) products in the near future.
About Sanguine Biosciences
Sanguine Biosciences is leading the charge in enhancing personalized medicine by empowering individuals with access to their healthcare data. By facilitating participation in biomedical research, the company integrates annotated biospecimens with real-world data, playing a crucial role in biomarker discovery and validation studies. Sanguine supports translational and clinical research for over 30 top pharmaceutical and biotechnology companies worldwide, helping to accelerate research and development while improving drug manufacturing processes.
Recognized for its commitment to fostering a positive work environment, Sanguine has been honored as a "Great Place to Work" for four consecutive years. The company has also made the Inc. 5000 list of America's Fastest Growing Private Companies and received accolades from Fortune as one of the Best Workplaces in BioPharma and one of the Best Small Workplaces.
Frequently Asked Questions
What ISO certifications did Sanguine Biosciences achieve?
Sanguine Biosciences achieved ISO 9001, ISO 27001, and ISO 27701 certifications.
Why are these certifications significant?
These certifications validate Sanguine's commitment to quality management, information security, and privacy management, enhancing trust among customers and partners.
What does the ISO 9001 certification signify?
The ISO 9001 certification signifies that Sanguine maintains high standards in their quality management system, ensuring customer satisfaction.
How does Sanguine ensure data security?
Sanguine follows stringent protocols and achieved ISO 27001 certification to protect data, addressing rising concerns about data breaches and security threats.
What is the vision of Sanguine Biosciences?
Sanguine aims to accelerate personalized medicine adoption by empowering individuals with their healthcare data and promoting participation in biomedical research.
